This study is currently not recruiting participants.

TBCRC026; A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Investigating Imaging Techniques to Predict Treatment Response in Breast Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

Detailed description of study

This study will evaluate for the first time the correlation between early changes in SUV and pCR in men and women with ER-negative, HER2-positive breast cancer receiving trastuzumab and pertuzumab (PT) pre-operatively.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the use of PET (Positron Emission Tomography) imaging to predict treatment response in patients with breast cancer. The purpose is to see if early changes in PET scans can indicate how well patients will respond to a combination of investigational medications given before surgery. PET is a type of imaging that helps doctors see how organs and tissues inside the body are working.

Participants will undergo PET scans to measure changes in a specific value known as SUV, which stands for Standardized Uptake Value. This study will look at how these changes relate to the effectiveness of the treatment, measured by a term called pCR, which stands for pathological complete response. The investigational medications will be administered before surgery as part of the study procedures.

  • Who can participate: Participants must be men or women diagnosed with ER-negative, HER2-positive breast cancer. They should be receiving trastuzumab and pertuzumab.
  • Study details: Participants will undergo PET scans to monitor changes. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1311763012

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team